MOORESTOWN, N.J., Oct. 11, 2016 -- Tabula Rasa HealthCare (NASDAQ:TRHC) Chairman and CEO Calvin H. Knowlton, PhD, today announced changes to TRHC’s corporate C-suite.
Current General Counsel and Chief Strategy Officer, Brian J. Litten, Esq., is being promoted to lead the new Office of Strategy Development (OSD). In this expanded role, Litten will retain his title of Chief Strategy Officer. He will oversee all product development, sales and implementation focused on new markets outside of the company’s PACE (Programs of All-Inclusive Care for the Elderly) market. The OSD team will be developed over the next six months.
The OSD was created to formalize the expansion of TRHC’s Medication Risk Mitigation™ platform. According to CEO Knowlton, the OSD will target markets for TRHC’s Medication Risk Mitigation (MRM) platform, which are separate from its ongoing PACE market. “We have asked Brian Litten, Esq., formerly a health insurance company executive, to lead this new initiative under his continued title as Chief Strategy Officer,” Knowlton reported.
“We also are pleased to announce Kevin J. Dill, Esq., will serve as TRHC’s General Counsel and Chief Compliance Officer,” Knowlton said. “Kevin brings valuable public-company experience in the areas of risk assessment, compliance oversight, and efficiency of healthcare operations. I have asked Brian and Kevin to collaborate over the next few months to transition TRHC’s legal work to the Office of General Counsel. Until the completion of this transition, Brian will continue to serve as our General Counsel, while building the new Office of Strategic Development.”
Dill comes to TRHC from Olympus Corporations of the Americas, where he served as Chief Compliance Officer handling implementation of comprehensive compliance procedures and assessments across Americas for the $2.5B medical device and consumer products company with a field force of over 1,000 sales representatives and distributor network. He is recognized for leading healthcare businesses in design and execution of strategies that ensure operations are in full compliance with laws and regulations, and for providing guidance to company executives and Board of Directors on compliance risks and remediation strategies.
Dill received a Juris Doctor (JD) degree from Temple University, Beasley School of Law, Philadelphia, PA; Doctor of Ministry (DMin), Princeton Theological Seminary; and Bachelor of Arts (BA), Gettysburg College, Gettysburg, PA.
Dill will begin his tenure at TRHC starting October 17, 2016.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.TRHC.com.
Contact: Media Dianne Semingson [email protected] T: 215-870-0829 Investors Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 [email protected]


TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 



